Overview

Vascular Inflammation in Psoriasis - Apremilast

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the VIP-A study is to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Celgene Corporation
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Apremilast
Thalidomide